Pharma: Page 23
-
Warren Little via Getty Images
GSK sales of RSV vaccine stay strong, beating forecast
The British drugmaker reported Arexvy sales of about $1.5 billion for 2023, higher than the range it had previously predicted for the year.
By Delilah Alvarado • Jan. 31, 2024 -
Getty Images
Novo resumes supplying starter doses of obesity drug Wegovy
The announcement ends a nine-month delay related to manufacturing snags that slowed Novo’s ability to meet demand for the fast-selling medicine.
By Jonathan Gardner • Jan. 31, 2024 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Permission granted by Bristol-Myers Squibb
Bristol Myers gets positive data in subcutaneous Opdivo trial
An under-the-skin Opdivo shot produced similar results to an intravenous formulation in kidney cancer, giving Bristol Myers a chance at sustaining sales past a key patent expiration in 2028.
By Jonathan Gardner • Jan. 29, 2024 -
Mike Coppola via Getty Images
J&J focuses on newer meds to offset Stelara patent cliff
Executives talked up the company’s cash position and incremental dealmaking as ways to buttress against incoming competition.
By Michael Gibney • Jan. 24, 2024 -
Getty Images
Gilead ADC medicine misses goal in closely watched lung cancer study
Trodelvy didn’t outperform chemotherapy in a large study of people with a common lung tumor, a setback that sent company shares down by double digits.
By Jonathan Gardner • Jan. 22, 2024 -
Getty Images
Sanders threatens to subpoena J&J, Merck CEOs over drug prices
The Senate HELP committee, which is seeking testimony from J&J's Joaquin Duato and Merck's Robert Davis, hasn't issued a subpoena since 1981.
By Jonathan Gardner • Jan. 19, 2024 -
Permission granted by Takeda Pharmaceuticals
Five years after Shire deal, Takeda hopes to reap rewards of latest reinvention
Amid scrutiny of Takeda’s past megamerger, Chief Scientific Officer Chris Arendt said it has built a drug pipeline that will deliver.
By Meagan Parrish • Jan. 19, 2024 -
Sean Gallup via Getty Images
Bayer signals ‘significant’ layoffs in plan to shrink bureaucracy
The company said it has secured agreement from labor representatives in Germany for job cuts that will shed “many managerial employees.”
By Kristin Jensen • Jan. 18, 2024 -
Courtesy of Vertex Pharmaceuticals
FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia
The agency’s decision to expand use of Casgevy, which won a landmark OK for sickle cell disease in December, comes two months ahead of schedule.
By Ned Pagliarulo • Jan. 16, 2024 -
Permission granted by ClinicalMind
Sponsored by ClinicalMindSimplifying speaker engagement in Pharma: A holistic approach
Relationships with Speaker Bureau faculty are among the most important that a biopharmaceutical company nurtures.
Jan. 16, 2024 -
Brian Tucker / BioPharma Dive/BioPharma Dive
The biopharma industry outlook on 2024: Guarded optimism for a rebound
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
By Ned Pagliarulo • Jan. 16, 2024 -
Mario Tama / Getty via Getty Images
FDA says no ‘clear relationship’ between GLP-1 drugs and suicide risk
Regulators will continue to evaluate suicide ideation as the data don't "definitively rule out" an association.
By Jonathan Gardner • Jan. 12, 2024 -
Getty Images
5 questions facing pharma in 2024
New drugs for obesity and cancer are the focus of many pharma companies, some of which are also grappling with how to manufacture complex cell and gene therapies.
By Jonathan Gardner , Ned Pagliarulo • Jan. 10, 2024 -
Danielle Ternes/BioPharma Dive
JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense
Radiopharma drugmakers spoke with BioPharma Dive about chasing Novartis in the hot field, while Bluebird’s CEO explained the company’s sickle cell therapy pricing.
By Ben Fidler , Ned Pagliarulo , Gwendolyn Wu • Jan. 10, 2024 -
Danielle Ternes/BioPharma Dive
JPM24: Pfizer’s tough sell, the next Karuna and building a biotech platform
Albert Bourla acknowledged Pfizer’s difficult 2023, while PureTech’s Daphne Zohar spoke with BioPharma Dive about building neuroscience startups.
By Ben Fidler , Delilah Alvarado • Jan. 9, 2024 -
Warren Little via Getty Images
GSK to buy asthma drug startup Aiolos for $1B
Aiolos, which raised a Series A round three months ago, is developing an antibody that shares a target with Amgen and AstraZeneca’s Tezspire.
By Ned Pagliarulo • Jan. 9, 2024 -
Danielle Ternes/BioPharma Dive
JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job
The chip maker struck a new deal with Amgen last Monday, while Sarepta brought news of strong sales to the J.P. Morgan Healthcare Conference.
By Gwendolyn Wu , Delilah Alvarado , Ben Fidler • Jan. 8, 2024 -
Kena Betancur via Getty Images
Merck pays $680M for struggling cancer biotech Harpoon
The acquisition will build out Merck’s pipeline of immunotherapies as its top-seller Keytruda nears the end of U.S. market exclusivity.
By Jonathan Gardner • Jan. 8, 2024 -
Mario Tama via Getty Images
J&J to acquire ADC drug developer Ambrx for $2B
The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.
By Ned Pagliarulo • Jan. 8, 2024 -
Getty Images
Novo taps Flagship startups to develop drugs for obesity, MASH
The research deals with Omega Therapeutics and Cellarity are the first under a broad alliance Novo struck with Flagship last spring.
By Kristin Jensen • Jan. 4, 2024 -
Getty Images
Roche joins startup Remix in bet on another way to drug RNA
The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.
By Ben Fidler • Jan. 3, 2024 -
Permission granted by Novartis
Novartis deepens ties with Voyager via $100M gene therapy deal
The deal builds on an existing alliance and includes tools Novartis will use in gene therapies for Huntington’s disease and spinal muscular atrophy.
By Delilah Alvarado • Jan. 2, 2024 -
Permission granted by Bristol-Myers Squibb
Bristol Myers to acquire brain drug developer Karuna for $14B
The deal would hand Bristol Myers, which is reprioritizing neuroscience research, an experimental treatment for schizophrenia that analysts think could become a blockbuster product.
By Ned Pagliarulo , Ben Fidler • Updated Dec. 22, 2023 -
Courtesy of Sanofi
Sanofi scraps a top ADC prospect after study setback
The drug, acquired via a deal with ImmunoGen, was the most advanced experimental medicine in the French pharma’s pipeline.
By Ben Fidler • Dec. 21, 2023 -
Warren Little via Getty Images
GSK adds to ADC dealmaking with second Chinese biotech pact
The deal with Hansoh Pharma, GSK’s second this year, gives the company an antibody-drug conjugate in testing for solid tumors like lung cancer.
By Jonathan Gardner • Dec. 20, 2023
Previous
